Targeting extracellular matrix proteolysis for hemorrhagic complications of tPA stroke therapy.
To date, tPA-based thrombolytic therapy is the only FDA-approved treatment for achieving vascular reperfusion and clinical benefit, but this agent is given to only about 2-5% of stroke patients in the United States of America. This may be related, in part, to the elevated risks of symptomatic intracranial hemorrhage, and the consequently reduced therapeutic time window. Recent efforts have aimed at identifying new combination strategies that might increase thrombolytic efficacy of tPA to benefit reperfusion, while reducing its associated neurotoxicity and hemorrhagic complications. Emerging experimental studies demonstrate that the breakdown of neurovascular matrix initiates blood-brain barrier disruption with edema and/or hemorrhage. Perturbation of extracellular homeostasis triggered by dysregulated extracellular proteases may underlie processes responsible for the hemorrhagic complications of thrombolytic stroke therapy. This short review summarizes experimental investigations of this field in pre-clinical stroke models. The data strongly suggest that targeting the extracellular matrix proteolytic imbalance within the neurovascular unit may provide new approaches for improving the safety and efficacy of thrombolytic reperfusion therapy of stroke.
Wang
Xiaoying
X
Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA. wangxi@helix.mgh.harvard.edu
Rosell
Anna
A
Lo
Eng H
EH
D000818:Animals; D004789:Enzyme Activation / Q000187:drug effects; D005109:Extracellular Matrix / Q000378:metabolism*; D006470:Hemorrhage / Q000378:metabolism*; D006801:Humans; D020521:Stroke / Q000150:complications / Q000188:drug therapy; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
D010959:Tissue Plasminogen Activator